Optimization of the Solvent and In Vivo Administration Route of Auranofin in a Syngeneic Non-Small Cell Lung Cancer and Glioblastoma Mouse Model

The antineoplastic activity of the thioredoxin reductase 1 (TrxR) inhibitor, auranofin (AF), has already been investigated in various cancer mouse models as a single drug, or in combination with other molecules. However, there are inconsistencies in the literature on the solvent, dose and administra...

Descripción completa

Detalles Bibliográficos
Autores principales: Freire Boullosa, Laurie, Van Loenhout, Jinthe, Hermans, Christophe, Lau, Ho Wa, Merlin, Céline, Marcq, Elly, Takhsha, Farnaz Sedigheh, Martinet, Wim, De Meyer, Guido R. Y., Lardon, Filip, Smits, Evelien L. J., Deben, Christophe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9783082/
https://www.ncbi.nlm.nih.gov/pubmed/36559255
http://dx.doi.org/10.3390/pharmaceutics14122761

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9783082/
https://www.ncbi.nlm.nih.gov/pubmed/36559255
http://dx.doi.org/10.3390/pharmaceutics14122761

Ejemplares similares